abstract |
The present invention relates to an immunostimulatory cell targeting CLD18A2, a method for its production and use. The inventors have successfully discovered a target gene CLD18A2 suitable for studying CAR-engineered immune effect cells in a number of tumor-associated genes and have successfully produced CAR-engineered immune effect cells targeting CLD18A2 to treat tumors such as pancreatic cancer and stomach cancer Provide a new means of treatment. |